ÍþÁ®Ï£¶û¹ÙÍøµØÖ·

ÈÈÃÅËÑË÷
Ó¢¹ú¡¤ÍþÁ®Ï£¶û(williamhill)ΨһÖÐÎĹٷ½ÍøÕ¾ Ó¢¹ú¡¤ÍþÁ®Ï£¶û(williamhill)ΨһÖÐÎĹٷ½ÍøÕ¾
ÐÂÎÅ×ÊѶ
Ó¢¹ú¡¤ÍþÁ®Ï£¶û(williamhill)ΨһÖÐÎĹٷ½ÍøÕ¾
2026-02-11
¿Í»§µÄ ¡°ÕÙ»½¡± £¬ÎÒÃÇÕâÑù»ØÓ¦
2025 ÍþÁ®Ï£¶û¹ÙÍøµØÖ·Äê¶È·þÎñ±¨¸æ ¡ª¡ªÒÔ·þÎñÖ®¹â£¬ÕÕÁÁ¿Æ¼¼Ö®Â·¡ª¡ª¡°ÒÔ¿Í»§ÎªÖÐÐÄ¡±ÊÇÍþÁ®Ï£¶û¹ÙÍøµØÖ·ÉúÎïµÄ·þÎñ×ÚÖ¼ÎÒÃÇÓÅ»¯Á÷³Ì¡¢Á¢Òì¼Æ»®ÓÃÐж¯Ú¹ÊÍ·þÎñ¼ÛÖµÓÃרҵÓëζÈÓ®µÃ¿Í»§ÐÅÈÎÕâÒ»ÄêÀۼƷþÎñ16,000+¼Ò¿Í»§·þÎñ×ã¼£±é²¼10¡­
Éó²éÏêÇé
Ó¢¹ú¡¤ÍþÁ®Ï£¶û(williamhill)ΨһÖÐÎĹٷ½ÍøÕ¾
112026.02
?ÍþÁ®Ï£¶û¹ÙÍøµØÖ·¸ºÑ¹¸ôÀëÆ÷ÊÖÒÕÔڸ߻îÐÔÖÊÁÏÒ©Éú²úÖеÄÓ¦ÓÃ
Ò»¡¢¹æÔò¶Ô¶¾ÐÔÒ©Æ·Éú²úµÄÏà¹Ø»®¶¨¡ñ WHO TRS-957 ANNEX 3 WHO good manufacturing practices for pharmaceutical products containing hazardous substance¡­
Ó¢¹ú¡¤ÍþÁ®Ï£¶û(williamhill)ΨһÖÐÎĹٷ½ÍøÕ¾
302026.01
ÍòÂíÍØÐ ¹²Ô¾É½º£ | ÍþÁ®Ï£¶û¹ÙÍøµØÖ·ÉúÎï2025Äê¶È×ܽá±íÑï´ó»áÔ²ÂúÂäÄ»£¡
1ÔÂ28ÈÕ£¬¡°ÍòÂíÍØÐ ¹²Ô¾É½º£¡±¡ª¡ªÍþÁ®Ï£¶û¹ÙÍøµØÖ·ÉúÎï2025Äê¶È×ܽá±íÑï´ó»áÊ¢´ó¾ÙÐÐ ¡£ÍþÁ®Ï£¶û¹ÙÍøµØÖ·¶­Ê³¤Ò¶´óÁÖÏÈÉú£¬ÍþÁ®Ï£¶û¹ÙÍøµØÖ·¸±×ܲÃÉòÖ¾ÁÖÏÈ¡­
Ó¢¹ú¡¤ÍþÁ®Ï£¶û(williamhill)ΨһÖÐÎĹٷ½ÍøÕ¾
232026.01
ϲ±¨£¡ÍþÁ®Ï£¶û¹ÙÍøµØÖ·ÆÊÎö»ñÅú¡°Õã½­Ê¡ÆóÒµÑо¿Ôº¡±£¬Ñз¢ÊµÁ¦»ñÊ¡¼¶È¨ÍþÈÏÖ¤£¡
¿ËÈÕ£¬Õã½­ÍþÁ®Ï£¶û¹ÙÍøµØÖ·ÆÊÎöÒÇÆ÷ÓÐÏÞ¹«Ë¾ÒÀ¸½ÉîÖ¿µÄÊÖÒÕ»ýµí¡¢Ò»Á¬µÄÁ¢ÒìÄÜÁ¦ÓëÐÐÒµÁìÏȵÄÑз¢Ë®Æ½£¬ÀֳɻñÅú¡°Õã½­Ê¡ÍþÁ®Ï£¶û¹ÙÍøµØÖ·ÖÇÄÜ»¯ÆÊÎöÒÇÆ÷ÆóÒµÑо¿Ôº¡±£¨Õ㾭ПßÐÂ˽º¯¡²2025¡³165ºÅ¡­
Ó¢¹ú¡¤ÍþÁ®Ï£¶û(williamhill)ΨһÖÐÎĹٷ½ÍøÕ¾
162026.01
ÍþÁ®Ï£¶û¹ÙÍøµØÖ· MD500 ΢ÉúÎï¿ì¼ì²úÆ·»ñʡҩ¼ìԺȨÍþÑéÖ¤£¬Íƶ¯ÖÆÒ©ºÏ¹æ¼ì²âÉý¼¶
¿ËÈÕ£¬Õã½­ÍþÁ®Ï£¶û¹ÙÍøµØÖ·ÆÊÎöÒÇÆ÷ÓÐÏÞ¹«Ë¾MD500ÐÍ΢ÉúÎï¿ìËÙ¼ì²âÆÊÎöÒÇ˳Ëìͨ¹ýÕ㽭ʡʳÎïÒ©Æ·Ä¥Á·Ñо¿ÔºÌæ»»ÒªÁìѧÑéÖ¤²¢ÕýʽȡµÃÑéÖ¤Ö¤Ê飬±ê¼ÇןòúÆ·¿ÉʵÏֹŰå΢ÉúÎïÄ¥Á·ÒªÁì¡­
Ó¢¹ú¡¤ÍþÁ®Ï£¶û(williamhill)ΨһÖÐÎĹٷ½ÍøÕ¾
092026.01
ϲ±¨!ÍþÁ®Ï£¶û¹ÙÍøµØÖ·GMP¼¶È«ÃܱÕϸ°ûÖÆ±¸ÏµÍ³±»È϶¨ÎªÊ×̨£¨Ì×£©×°±¸
ÍþÁ®Ï£¶û¹ÙÍøµØÖ·ÉúÎïCGTÒ©Î﹤ҵ»¯½â¾ö¼Æ»®£¨1£©»ùÓÚCGTÒ©ÎïÉú²ú¹¤ÒÕºÍGMPÎÞ¾ú»¯Éú²úÒªÇ󣬣¨2£©Ñз¢µÄÈ«ÃܱÕʽϸ°ûÒ©ÎïÖÆ±¸ÊÂÇéÕ¾Óë·ä³²Ê½Ï¸°û×÷Óýϵͳ£¬£¨3£©¿ÉÈ¡´ú¹Å°å¡°B¡­
ÍøÕ¾µØÍ¼